88
1 November 2016 Research in Your Backyard: Japan Contribution of PhRMA and EFPIA Member Companies to Japanese Society & Economy Through Clinical Trials of Innovative Medicines
1
November 2016
Research in Your Backyard: Japan
Contribution of PhRMA and EFPIA Member Companies to Japanese Society & Economy
Through Clinical Trials of Innovative Medicines
2
Introduction: Who We Are 3
Pharmaceutical Industry and Society 5
Collaborating on Clinical Trials 7
R&D Spending, Trends, and Results 14
Summary: For Japanese society and patients 20
Contents
3
Introduction: Who We Are
We are devoted to advancing public policies that support innovative medical research,yield progress for patients today, and provide hope for the treatments and cures of tomorrow
Mission
PhRMA Japan’s missionis to promote the health
of patients and contributeto the healthier lives of
all people
Mission
EFPIA Japan’s mission isto enhance the health of
Japanese patients byintroducing innovative
drugs and vaccines
PhRMA Japan represents U.S. basedpharmaceutical companies. Our
activities vary from promoting healthcaresystem reform to providing medical
information to patients.
EFPIA Japan represents R&D-based Europeanpharmaceutical companies. We focus on patientneeds in Japan, engage in discussions with keystakeholders regarding public health, and work
to improve the R&D environment forpharmaceutical companies.
4
PhRMA and EFPIA member companies
PhRMA EFPIA
AbbVie GK
Amgen Astellas BioPharma K.K.
Biogen Japan Ltd.
Bristol-Myers Squibb K.K.
Celgene K.K.
Eli Lilly Japan K.K.
Janssen Pharmaceutical K.K.
MSD K.K.
Mundipharma K.K.
Pfizer Japan Inc.
Actelion Pharmaceuticals Japan Ltd.
AstraZeneca K.K.
Bayer Yakuhin, Ltd
Bracco-Eisai Co., Ltd.
Chugai Pharmaceutical Co., Ltd.
CSL Behring K.K.
Ferring Pharmaceuticals Co., Ltd.
Galderma (Japan) K.K.
GE Healthcare Japan Corporation
GlaxoSmithKline K.K.
Guerbet Japan K.K.
Ipsen Pharma SAS
Janssen Pharmaceutical K.K.
LEO Pharma K.K.
Lundbeck Japan K. K.
Merck Serono Co.,Ltd.
Mylan EPD G.K.
Nihon Servier Co.,Ltd.
Nippon Boehringer Ingelheim Co ., Ltd.
Novartis Pharma K.K.
Novo Nordisk Pharma Ltd.
Sanofi K.K.
Shire Japan K.K.
UCB Japan Co. Ltd.
5
Pharmaceutical Industry and Society
6
Pharmaceutical companies contribute to society andthe economy in multiple ways
Pharmaceutical companies collaborate with local clinics and hospitals to develop new drugs.This in turn provides economic stimulus and leads to innovative new medicines with better efficacy and safety profiles.
IncreasingProductivity
CreatingJobs
ImprovedSafety
BetterEfficacy
ClinicalTrials
BasicResearch
DrugDevelopment
EconomicStimulation
Innovative Drugs toPromote Healthier and
Longer Lives
Pharmaceutical Industry and Society
7
Collaborating on Clinical Trials
8
Discovering and developing new medicines is a long,complex, and costly process
Developing innovative medicines takes an average of 10-15 years and 2.6B USD. Less than 12% of the candidate medicines that make it into phase I clinical trials are approved. Many promising compounds fail
after pharmaceutical companies have spent substantial amounts of money on testing and clinical trials
DrugDiscovery Preclinical Clinical
TrialsRegulatory
ReviewScale-upto MFG.
Post-Marketing
Surveillance
PR
E-D
ISC
OV
ER
Y
Apply to conduct clinical trial
Apply for new
drug approval
PHASE3PHASE2
3-6 YEARS
PHASE1
6-7 YEARS 0.5-2 YEARS …
Source: Cost of Developing a New Drug, Tufts Center for the Study of Drug Development, Tufts School of Medicine. November 2014.
Collaborating on Clinical Trials
9
What is a Clinical Trial?
Computer simulations and animal testing are not enough to determine the efficacy and safety of new drugs for people.Clinical trials are conducted in five phases with the aim of clarifying the impact of experimental drugs on humans.
Collaborating on Clinical Trials
Phase 0First-in-human trial with a small number of healthy adults (10 to 15)to gather data on what the drug does to the body and what the bodydoes to the drug
Phase 1Trial to test a drug with a small number of healthy adults (20 to 80) totest safety, determine a safe dosage range and identify side effects
Phase 2First trial using actual patients (100 to 300) to test efficacy of a newdrug and further evaluate its safety
Phase 3Trial with an increased number of patients (1,000 to 3,000) in order toconfirm its effectiveness, monitor side effects, and to compare it toexisting treatments
Phase 4After a new drug has been approved, Post Marketing Surveillance ofactual usage is conducted to confirm that the drug acts as expected
Source: PhRMA
Therapeutic Area Example
10
Allergy
Infectious disease
Hematology
Respiratory disease
Oncology
Cardiology
Gastroenterology
CNS
Urology
Dermatology
Ophthalmology
Immunology
Musculoskeletal disease
Endocrine metabolic disease
Rare disease
What are Therapeutic Areas?
Therapeutic areas are general categories of illnesses, including the examples below
Allergic rhinitis, Asthma, Atopic dermatitis, etc.
Influenza, Hepatitis C/B, Herpes, etc.
Anemia, Hemophilia, etc.
COPD, Bronchiectasis, etc.
Gastric cancer, Lung cancer, Breast cancer, etc.
Heart failure, Brain ischemia, Hypertension, etc.
Gastric ulcer, Reflux esophagitis, etc.
Alzheimer’s disease, Depression, Epilepsy, etc.
Nocturia, Lupus nephritis, etc.
Acne, etc.
Age-related macular degeneration, Uveitis, etc.
Rheumatoid arthritis, Crohn’s disease, Psoriasis, etc.
Osteoporosis, Lower back pain, etc.
Diabetes mellitus, Hypercholesterolemia, Hyperphosphatemia, etc.
Gaucher disease, Myelofibrosis, Behcet’s disease, etc.
Collaborating on Clinical Trials
11
Collaborating with Japanese institutions in conducting and supporting clinical trials
Conducting clinical trials involves collaboration between pharmaceutical companies and other institutions in Japan,such as hospitals, local clinics, and contract research organizations (CRO).
Collaborating on Clinical Trials
PEER REVIEWEDJOURNAL
DATA
REGULATORYAGENCY
DATA
CLINICHOSPITAL
PATIENTS
Decide to conduct clinical trialsand request support from CRO
Support pharmaceutical companieswith the coordination of clinical trials
Conduct trials performed by physicians and trained research professionals
Provide additional support to hospitalsand clinics during trials
CROPHARMACEUTICAL
COMPANIES
SMO
Pharmaceutical Companies CRO Hospitals / Clinics SMO(Site Management Organizations)
12
Partnering with local Japanese medical institutions to conduct clinical trialsexpands the benefit of clinical trials to the hosting area
Conducting clinical trials for new drug development contributes to local Japanese economiesand improves the quality of life for people in Japan
Providing advancedtreatment
Medical facilities conducting clinical trials are able to provideadvanced medical treatments to their patients in these locales
Contributing tolocal economy
The spending on clinical trials in Japan goes to hospitals and clinicsnationwide and supports local economies
Creating jobs Related stakeholders (local medical facilities and pharmaceuticalcompanies) employ local staff to support clinical trials
Collaborating on Clinical Trials
13
PhRMA and EFPIA member companies conducted 825 clinical trials in 2015to deliver innovative medicines to patients in Japan
825CLINICAL TRIALS*
18,095SITES**
# of clinical trial conducted
201 ～
101 ～ 200
31 ～ 100
16+THERAPEUTIC AREAS
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
Source: www.clinicaltrials.gov (2015 data)*Figures do not include post marketing surveillance **Individual sites participating in multiple trials are counted multiple times
Collaborating on Clinical Trials
(+21% since 2013)
(+55% since 2013)
14
PhRMA and EFPIA member companies conduct many clinical trialsacross all prefectures of Japan
Kanto Koshinetsu
Source: www.clinicaltrials.gov (2015 data)
Tohoku
Shikoku
Hokkaido
Hokuriku
Chugoku
Kyushu
Kinki
Tokai
Hokkaido 325
Toyama 76Ishikawa 130Fukui 65
Osaka 438Hyogo 324Kyoto 191Shiga 61Nara 67Wakayama 66
Tottori 43Shimane 56Okayama 188Hiroshima 183Yamaguchi 100
Fukuoka 415Saga 75Nagasaki 112Kumamoto 166Oita 93Miyazaki 59Kagoshima 128Okinawa 86
Tokushima 79Kagawa 107Ehime 174Kochi 78
Aichi 390Gifu 103Shizuoka 241Mie 100
Tokyo 611Kanagawa 359Saitama 237Chiba 346Ibaraki 173Tochigi 119Gunma 148Yamanashi 58Nagano 123Niigata 124
Aomori 67Iwate 93Miyagi 215Akita 57Yamagata 53Fukushima 86
Prefecture not specified 147
Collaborating on Clinical Trials
15
R&D Spending, Trends, and Results
16
PhRMA and EFPIA member companies contribute a significant shareof the research and development spending in Japan
Source: JPMA data based on company disclosures for fiscal year 2014* 72 JPMA companies ** 19 PhRMA and EFPIA member companies participating in JPMANote: The figures refer only to clinical research related spending during fiscal year 2014 disclosed by JPMA member companies
2014 Clinical Trial RelatedSpending in Japan Total*
R&D Spending, Trends, and Results
204B JPY
79B JPY2014 Clinical Trial RelatedSpending in Japan: PhRMA and EFPIA Subtotal**
17R&D Spending, Trends, and Results
Source: PhRMA and EFPIA Japan joint research of 28 member companies (clinical trials conducted between April 2015 and March 2016)“Drug lag” refers to the delay to approve a new drug in Japan such as cases where approval is delayed compared to other countries, such as the U.S. and EuropeConducting more global simultaneous clinical trials shortens the drug lag**Simultaneous international submission refers to the submission of a new drug application (NDA) at the similar timing (within 3 months, in this study) as other countries, such as the U.S. and Europe
Reducing the “drug lag*”
PhRMA and EFPIA member companies are planning simultaneous international drug submissions**which will allow Japanese patients to be in the first wave of access to innovative medicines
Simultaneous international submissions plannedby PhRMA / EFPIA member companies
Completed simultaneous international submissions
Planned simultaneous international submissions
Simultaneous international submissions is not planned or not feasible
Simultaneous international submissions is under consideration
4%
45%
34%
17%
18
Number of New Drugs Approved in Japan
Source: PMDA website *New drugs refer to New Molecular Entities only approved between April 2007 and March 2016 (Other approvals, such as new indications, are excluded)Besides the approvals obtained by PhRMA and EFPIA member companies, other approvals include products licensed from global companies
R&D Spending, Trends, and Results
19
(49%)
39
2013
26
(52%)
50
2014
23
(55%)
42
2015
22
2007
21
(57%)
37
20
(61%)
33
2008
18
(67%)
27
2009
20
(51%)
39
2010
22
(55%)
40
2011
16
(37%)
43
2012
Bringing innovation to Japanese patients
PhRMA and EFPIA member companies obtained approvalfor 185 new drugs* in Japan over the last 9 years
Japan Total
PhRMA and EFPIA Member Companies
19
Source: PMDA website *New indications refer to New Molecular Entities approved between April 2007 and March 2016, as well as new indications approved for existing drugsBesides the approvals obtained by PhRMA and EFPIA member companies, other approvals include products licensed from global companies
R&D Spending, Trends, and Results
33
(52%)
63
36
(59%)
61
38
(50%)
76
35
(46%)
76
55
(54%)
102
41
(42%)
97
41
(47%)
88
48
(52%)
92
46
(47%)
97
2013 2014 20152007 2008 2009 2010 2011 2012
Continuing investment in Japan to treat more conditions
PhRMA and EFPIA member companies obtained approvalfor 373 new indications* in Japan over the last 9 years
Number of New Indications Approved in Japan
Japan Total
PhRMA and EFPIA Member Companies
20
Summary: For Japanese society and patients
We are devoted to advancing public policies that support innovative medical research,yield progress for patients today, and provide hope for the treatments and cures of tomorrow
PhRMA and EFPIA member companies’ clinical research stimulates local economies through:- Collaboration with local Japanese clinics and hospitals to develop new drugs
- Funding clinical trials to develop innovative new medicines with better efficacy and safety profiles
PhRMA and EFPIA member companies invest heavily in clinical trials across all prefectures Japan:- 825 (+21% since 2013) clinical trials across more than 16 therapeutic areas conducted in 2015
- Rapid increase in clinical trials is the result of the premium for new drug development, introduced by the
Ministry of Health, Labour and Welfare in 2010
PhRMA and EFPIA member companies make continuous efforts and investment in Japan to allow Japanese patients to be in the first wave of access to innovative medicines:- Spent 79B JPY in the research and development in Japan in 2014
- Contribute around half of the new drug approvals in Japan
21
To download an electronic version of this presentation,
please go to www.efpia.jp or www.phrma-jp.org, or scan the QR code above
22
Appendix - Research Activity Map
23
Prefecture Views
24
825CLINICAL TRIALS SITES 16+
THERAPEUTIC AREAS
Prefecture Views
18,095Japan
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
25
Aichi
15
Prefecture Views
390 973
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
26
Akita
13
Prefecture Views
57 116
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
27
Aomori
11
Prefecture Views
67 132
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
28
Chiba
16+
Prefecture Views
346 687
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
29
Ehime
14
Prefecture Views
174 269
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
30
Fukui
14+
Prefecture Views
65 115
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
31
Fukuoka
16+
Prefecture Views
415 1,110
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
32
Fukushima
14
Prefecture Views
86 204
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
33
Gifu
15+
Prefecture Views
103 215
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
34
Gunma
15+
Prefecture Views
148 291
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
35
Hiroshima
16+
Prefecture Views
183 392
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
36
16+
Prefecture Views
Hokkaido
325 912
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
37
Hyogo
16+
Prefecture Views
324 765
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
38
Ibaraki
16+
Prefecture Views
173 389
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
39
Ishikawa
16+
Prefecture Views
130 228
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
40
Iwate
15+
Prefecture Views
93 159
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
41
Kagawa
14
Prefecture Views
107 194
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
42
Kagoshima
14+
Prefecture Views
128 233
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
43
Kanagawa
16+
Prefecture Views
359 1,013
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
44
Kochi
13
Prefecture Views
78 125
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
45
Kumamoto
16+
Prefecture Views
166 294
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
46
Kyoto
16+
Prefecture Views
191 415
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
47
Mie
15+
Prefecture Views
100 202
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
48
Miyagi
16+
Prefecture Views
215 394
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
49
Miyazaki
14
Prefecture Views
59 108
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
50
Nagano
16+
Prefecture Views
123 260
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
51
Nagasaki
14
Prefecture Views
112 227
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
52
Nara
13
Prefecture Views
67 131
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
53
Niigata
13
Prefecture Views
124 218
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
54
Oita
13
Prefecture Views
93 169
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
55
Okayama
15+
Prefecture Views
188 320
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
56
Okinawa
11
Prefecture Views
86 146
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
57
Osaka
16+
Prefecture Views
438 1,484
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
58
Saga
11
Prefecture Views
75 123
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
59
Saitama
16+
Prefecture Views
237 652
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
60
Shiga
13
Prefecture Views
61 121
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
61
Shimane
13
Prefecture Views
56 89
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
62
Shizuoka
16+
Prefecture Views
241 490
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
63
Tochigi
14
Prefecture Views
119 213
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
64
Tokushima
14
Prefecture Views
79 128
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
65
Tokyo
16+
Prefecture Views
611 2,418
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
66
Tottori
13+
Prefecture Views
43 73
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
67
Toyama
13
Prefecture Views
76 149
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
68
Wakayama
12
Prefecture Views
66 114
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
69
Yamagata
12
Prefecture Views
53 110
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
70
Yamaguchi
13
Prefecture Views
100 198
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
71
Yamanashi
16+
Prefecture Views
58 98
Allergy
Cardiology
CNS
Rare Diseases
Endocrine Metabolic Disease
Gastroenterology
Hematology
Dermatology
Immunology
Infectious Disease
Musculoskeletal Disease
Ophthalmology
Respiratory Disease
Urology
Others
Oncology
CLINICAL TRIALS SITES
THERAPEUTIC AREAS
72
Therapeutic Area Views
73
29CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
722Allergy
TRIALS
Phase 14%
Phase 346%
Phase 223%
Phase 44% 29
Undefined23%
74
Cardiology
57CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
2,368
TRIALS
Phase 12%
Phase 354%
Phase 216%
Phase 47% 57
Undefined21%
75
CNS
49CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
714
TRIALS
Phase 110%
Phase 373%
Phase 210%
Phase 46%
49
76
Dermatology
7CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
111
TRIALS
Phase 114%
Phase 343%
Phase 229%
Phase 414%
7
77
Endocrine metabolic disease
82CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
3,739
82TRIALS
Phase 13%
Phase 353%
Phase 27%
Phase 415%
Undefined23%
78
Gastroenterology
8CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
432
TRIALS
Phase 338%
Undefined63%
8
79
Hematology
36CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
219
36TRIALS
Phase 231%
Undefined11%
Phase 358%
81Phase 221%
80
Immunology
81CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
3,163
TRIALS
Phase 13%
Phase 361%
Phase 43%
Undefined13%
81
Infectious disease
34CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
490
34TRIALS
Phase 03%
Phase 410% Phase 3
43%
Undefined30%
Phase 17%
Phase 27%
82
Musculoskeletal disease
11CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
213
11TRIALS
Phase 236%
Phase 49%
Phase 355%
83
Oncology
331CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
3,354
331TRIALS
Phase 125%
Phase 341%
Phase 227%
Phase 42%
Undefined6%
84
Ophthalmology
18CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
273
18TRIALS
Phase 26%
Phase 433%
Phase 317%
Undefined44%
28
85
Rare disease*
28CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
587
TRIALS
Phase 14%
Phase 346%
Phase 229%
Undefined21%
* Rare disease includes conditions such as:Gaucher Disease, Myelofibrosis, and Bahcet’s Disease,which could not be categorized into other therapeutic areas
86
Respiratory disease
20CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
1,209
20TRIALS
Phase 220%
Phase 45%
Phase 355%
Undefined20%
87
Urology
14CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
365
14TRIALS
Phase 115%
Phase 415%
Phase 362%
Undefined8%
88
Others
20CLINICAL TRIALS SITES PHASES
Therapeutic Area Views
136
20TRIALS
Phase 120%
Phase 320%
Phase 210%
Phase 415%
Undefined35%
